Resumen

HERNANDEZ RAMIREZ, Porfirio et al. Treatment of promyelocytic leukemia using transretinoic acid and intensive chemotherapy: Clinical and molecular progress. Rev Cubana Hematol Inmunol Hemoter [online]. 2002, vol.18, n.2, pp. 0-0. ISSN 1561-2996.

Forty nine patients diagnosed with promyelocytic leukemia were treated with retinoic acid (45-50 mg/m2/day) during induction; afterwards, a consolidation therapy was applied with daunorubicin and arabinosylcitosine, followed by a maintenance therapy with 6 mercaptopurine and methotrexate for 2 years and a half. An evolving clinical, hematological and molecular study was performed. Forty three patients achieved complete remission (88%); 9 (47%) of 19 patients and 18(90%) of 20 patients had reached molecular remission after induction and consolidation respectively. Global survival rate at 5 years was 65%±8% and event-free survival rate was 63%±7%. Disease-free survival rate was 71%± 7% in the same period

Palabras clave : LEUKEMIA PROMYELOCYTIC, ACUTE [drug therapy]; TRETINOIN; DAUNORUBICIN; CYTARABINE; DRUG THERAPY COMBINATION; EVOLUTION, MOLECULAR.